Summit Therapeutics Inc. said on Tuesday it would license China-based Akeso Inc.’s experimental cancer therapy in a deal worth up to $5 billion, sending its shares up 57% in premarket trade.
If you are not happy with the results below please do another search
50 search results for:
Pfizer Inc. and Clear Creek Bio Inc. on Tuesday announced a collaboration to identify a potential drug candidate and develop a new class of oral treatment against COVID-19, as Pfizer seeks to expand its anti-infective pipeline.
The United States is experiencing the highest levels of hospitalizations from influenza that it has seen in a decade for this time of year, the head of the U.S. Centers for Disease Control and Prevention (CDC) said on Monday, adding that 14 children have died so far this flu season.
The three costliest therapies under Medicare health insurance in the United States saw price hikes in 2020 but there was not enough evidence of new clinical benefits, the Institute for Clinical and Economic Review (ICER) said on Tuesday.
The United States on Tuesday urged delaying a deadline for a World Trade Organization decision relating to the production of COVID-19 treatments and tests, the U.S. trade representative’s office said.
Britain’s health regulator on Tuesday authorized a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country’s youngest children once the UK’s Joint Committee on Vaccination and Immunization (JCVI) agrees.
Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday.